Thermo Fisher Scientific recently got approval from the US Food and Drug Administration (FDA) for two blood-based tests to help providers to assess whether a hospitalized patient is going to develop preeclampsia with severe features within a two-week period. In this episode, Preeclampsia Foundation CEO Eleni Tsigas goes “Beyond the Headlines” to meet with clinical and research experts to talk about what this means for patients.